Rivaroxaban in non valvular atrial fibrillation: subgroups analysis

Submitted: August 19, 2015
Accepted: August 19, 2015
Published: August 19, 2015
Abstract Views: 1204
PDF: 861
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


After the ROCKET AF study main paper several subgroups analysis were recently published. These studies are useful to better evaluate the rivaroxaban efficacy and safety in different clinical conditions. Here the subgroup analysis of patients with moderate renal failure, heart failure and diabetes are presented. Post hoc data on patients who underwent an electrical or pharmacological cardioversion during ROKET AF follow up were available and here we analyze also the results of the first randomized study on electrical cardioversion in patients treated with new oral anticolagulants: the X-VeRT trial. A metanalysis of all the studies with rivaroxaban (one on stroke prevention in atrial fibrillation, two on acute coronary syndromes, four on deep venous thrombosis prophylaxis and two on pulmonary embolism treatment) with respect to the risk of myocardial infarction is examined.



PlumX Metrics


Download data is not yet available.


How to Cite

Greco, Cesare. 2015. “Rivaroxaban in Non Valvular Atrial Fibrillation: Subgroups Analysis”. Monaldi Archives for Chest Disease 82 (1). https://doi.org/10.4081/monaldi.2014.37.